Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074810 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
A Phase 1 study of Non-Small Cell Lung Cancer and KRAS Activating Mutation, sponsored by Verastem.
- Active
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT05074810: Active Phase 1 study of Non-Small Cell Lung Cancer and KRAS Activating Mutation, sponsored by Verastem.
NCT05074810 is a Phase 1 study of Non-Small Cell Lung Cancer and KRAS Activating Mutation that is active but no longer recruiting, run by Verastem. The registered enrollment target is 153 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074810, a Phase 1 study of Non-Small Cell Lung Cancer and KRAS Activating Mutation, is active but no longer recruiting, sponsored by Verastem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Primary Outcome
Assessment of Dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG avutometinib and sotorasib
- DRUG avutometinib and sotorasib and defactinib
Study Locations (20)
Texas
- Texas Oncology - Austin
- University of Texas Southwestern Medical Center - Dallas
- Texas Oncology - Fort Worth Cancer Center - Fort Worth
- Texas Oncology - Longview
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute, - Washington D.C.
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
- Ohio State University Brain and Spine Hospital - Columbus
Pennsylvania
- Consultants in Medical Oncology & Hematology - Broomall
- Alliance Cancer Specialists, - Horsham
Virginia
- Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Blacksburg
- Virginia Cancer Specialists, PC - Fairfax
Colorado
- Rocky Mountain Cancer Center, LLP - Boulder
Illinois
- Illinois Cancer Specialists - Arlington Heights
Maryland
- Maryland Oncology & Hematology, P.A. - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What the registry record for NCT05074810 still lists
NCT05074810 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which avutometinib and sotorasib is the first listed.
NCT05074810 names 20 study sites across 13 states, led by Texas, District of Columbia, Ohio.
Frequently Asked Questions
What is clinical trial NCT05074810 about?
NCT05074810 is a clinical study titled "Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients". This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C ...
What is the current status of trial NCT05074810?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2022-04-12. Estimated completion is 2027-04.
What conditions does trial NCT05074810 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, KRAS Activating Mutation.
What interventions are being tested in trial NCT05074810?
The interventions under investigation include: avutometinib and sotorasib (DRUG), avutometinib and sotorasib and defactinib (DRUG).
Who is sponsoring clinical trial NCT05074810?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05074810 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05074810's enrollment target sits among peer trials
153 196th of 454 higher than 259 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI